Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

COVID-19 pandemic may restrict patients’ access to medical marijuana

The COVID-19 pandemic is set to impact the pharmaceutical industry in a profound way, according to GlobalData, a leading data and analytics company. From postponed and suspended clinical trials to stockpiling of painkillers causing disruption to supply chains, the medical marijuana industry is also expected to be affected by the ongoing crisis.    GlobalData’s report: ‘Medical […]
Read more

High-dose chloroquine should not be used further for COVID-19 patients due to the QTc prolongation, says GlobalData

Recent results have shown that high-dose chloroquine has potential safety concerns resulting in QTc prolongation, a heart rhythm disorder that serves as a surrogate indicator for increased risk of drug-associated torsades de pointes (TdP). GlobalData believes that the preliminary data from this Phase II study indicates that high-dose chloroquine should not be used further for […]
Read more

Phase 2 Kevzara trial provides important insight into the management of COVID-19

Regeneron and Sanofi recently announced the preliminary results from the Phase II portion of an ongoing Phase II/III trial evaluating Kevzara (sarilumab), an antibody targeting the interleukin-6 (IL-6) receptor, in hospitalized patients with severe or critical respiratory illness caused by COVID-19. Angad Lotay MPharm, Infectious Diseases Analyst at GlobalData, comments: “Targeting the correct patient population […]
Read more

India needs to step up healthcare spending to combat outbreaks such as COVID-19 in future, says GlobalData

With an unexpected spike in COVID-19 cases, India has extended the countrywide lockdown till 17 May 2020. The move reflects India’s dependency on lockdown to contain the pandemic amid poor healthcare spending and infrastructure, says GlobalData, a leading data and analytics company. According to GlobalData COVID-19 dashboard, as of 04 May 2020, although India has  42,505 […]
Read more

Cereno Scientific’s novel CS-1 holds potential as it enters crowded PAH marke

Cereno Scientific’s preclinical candidate CS-1 (valproic acid) was recently granted Orphan Drug Designation (ODD) by the Food and Drug Administration (FDA) for the US market for pulmonary arterial hypertension (PAH) —a rare, fatal cardiopulmonary disease with no curative treatment. Provided its successful clinical development, CS-1 has the potential to carve out a space on the market, due to its novel mechanism of action, says GlobalData, a leading data and analytics company. […]
Read more

Digital transformation in healthcare services is accelerated by COVID-19

The fast-paced adoption of digital technologies is emerging as a key element of remodeling healthcare delivery and scaling up systems. While the risk-averse culture, legacy systems, regulation and compliance challenges are hindering the uptake of emerging technologies in healthcare services, COVID-19 may be the trigger that will accelerate digitalization in the sector, says GlobalData, a […]
Read more

UK start-up companies’ AI to accelerate search for COVID-19 treatment

Start-up companies in the UK are turning to artificial intelligence (AI) for analysis of existing drugs and new molecules. The use of AI in this way has the potential to rapidly accelerate the research and development (R&D) timeline, allowing faster COVID-19 drug development. The COVID-19 pandemic may be a tipping point in companies adopting AI-facilitated […]
Read more

Real-world evidence can help countries deal with the COVID-19 outbreak

Organizations are relying on real-world evidence (RWE) to help tcontain the spread of COVID-19. Real-world data can provide valuable insights to help organizations better understand, monitor and prepare for the any challenges that the outbreak presents, says GlobalData, a leading data and analytics company. In a GlobalData poll of 935 respondents, conducted from April 6–20, more […]
Read more

Pharmaceutical professionals say employee safety and supply chain disruption are top COVID-19 concerns in latest GlobalData survey

Pharmaceutical industry professionals around the world believe that employee safety and supply chain disruption are their businesses’ number one concerns from COVID-19, the latest survey data from GlobalData, a leading data and analytics company, suggests. GlobalData’s latest report, ‘Coronavirus Disease 2019 (COVID-19) Sector Impact: Pharmaceutical Trade and Supply Chain Survey – Q1 2020’, reveals that 21% […]
Read more

Favipiravir exports during COVID-19 outbreak reaffirm India’s position as ‘pharmacy to the world’, says GlobalData

Following the news that India-based Strides Pharma has developed and commenced the export of generic favipiravir antiviral tablets to potentially treat COVID-19 infection; Sasmitha Sahu, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “This is an opportunity to reaffirm that India is indeed the ‘pharmacy to the world’. As the […]
Read more

Gilead’s remdesivir use for COVID-19 could spill over beyond ideal patient groups, possibly straining supply, says GlobalData

With the EMA announcing today that it will start a rolling review of Gilead Sciences’ remdesivir for COVID-19 and wide expectations that US Emergency Use Authorization (EUA) will be locked in, reporting from Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company, notes that broad use beyond […]
Read more

IBD industry could be at risk during COVID-19

As the COVID-19 global pandemic grows with the UK, active inflammatory bowel disease (IBD) patients could be at a higher risk, as patients using prominent therapies such as Remicade and Humira could cause an increased risk of bacterial and viral infections, says GlobalData, a leading data and analytics company. In order to protect active IBD patients, […]
Read more

Pre-emptive planning and manufacturing support initiatives could help avoid potential shortages in cancer drugs amid COVID-19 pandemic

Concerns have arisen that treatments for cancer patients could be affected by shortages in cancer drug supply and distribution as valuable medical resources are being diverted for the management of the COVID-19 pandemic. The outbreak has overtaxed healthcare systems worldwide as countries are struggling to contain the spread of the infection, says GlobalData, a leading […]
Read more

Wockhardt’s QIDP status for WCK 6777 reflects unmet need and untapped market opportunity, says GlobalData

India-based Wockhardt Ltd has recently received US FDA qualified infectious disease product (QIDP) status for WCK 677 (currently filed Investigational New Drug Application/Clinical Trial Application (IND/CTA)) to treat complicated urinary tract infections, including pyelonephrits and intra-abdominal infections. WCK 6777 targets multidrug resistance bacterial infections where unmet need is high, translating to an untapped market opportunity, […]
Read more

Incyte and Eli Lilly may have JAK inhibitor mechanistic edge over Pfizer for COVID-19 while Theravance may be limited by nebulised approach

Interest in a class of drugs called JAK inhibitors to manage COVID-19 is building, and with three such therapies already approved for other diseases, the race to repurpose these treatments has kicked off. Incyte’s Jakafi and Eli Lilly’s Olumiant may have mechanism edge over Pfizer’s Xeljanz, according to reporting by Reynald Castañeda, Pharma Writer for the Investigative News team at […]
Read more

SeaStar Medical to test immunomodulating device for the treatment of COVID-19 patients

Following the announcement that SeaStar Medical will initiate a pilot study of aselective cytopheretic device (SCD) in COVID-19 patients; Azadeh Laffafian, Medical Device Analyst at GlobalData, a leading data and analytics company, offers her view: “SeaStar’s SCD targets proinflammatory neutrophils and monocytes during continuous renal replacement therapy (CRRT) to combat cytokine storm in severely ill […]
Read more
1 … 95 96 97 98 99 … 110